Detalhe da pesquisa
1.
The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV.
HIV Clin Trials
; 13(1): 33-45, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22306586
2.
Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease.
Clin Gastroenterol Hepatol
; 9(3): 242-8, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21056689
3.
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
Gastroenterology
; 139(5): 1593-601, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20637202
4.
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin.
Hepatology
; 51(6): 1897-903, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20196118
5.
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
Ann Intern Med
; 150(8): 528-40, 2009 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-19380853
6.
Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
Eur J Gastroenterol Hepatol
; 23(5): 375-81, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21502923
7.
Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
Eur J Gastroenterol Hepatol
; 23(11): 1004-10, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21904204